You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said it took in $33.6 million in product and service revenue in the quarter, a 42 percent increase from $23.6 million in Q4 2018.
Aiming to improve patient access to critical drugs and tests, a group of legislators have started a caucus to shore up bipartisan support for personalized medicine.
Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.
The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon reproductive health tests.
LabCorp will be the exclusive provider of the test, which uses next-generation sequencing to look for actionable mutations cell-free DNA in NSCLC patients.
The firm will use the funding to expand access to its microbial cell-free DNA technology to help doctors diagnose infectious disease.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.
The companies will join their respective technologies to provide pharmacogenomic information for patients undergoing genetic testing.
The Series B round, which includes new and existing investors, follows the Belgian firm's completion of a €7.7 million private placement in 2016.
HTG will leverage existing collaborations with firms including Illumina and Thermo Fisher Scientific to continue building in vitro diagnostic assays on their sequencers.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
The project, the first under a partnership between the university and Illumina announced last year, will apply whole-genome sequencing to challenging cancers types.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
The agency aims to aid adoption of NGS within public health labs, which have significantly increased their use of the technology in recent years.
PacBio will try to take the Sequel II to the clinic in China with the help of Berry Genomics and is open to partnerships globally, including with Illumina.
The company expects that Blueprint's informatics capabilities in particular will improve variant interpretation and reporting across all its genetic test offerings.
The company's approach involves using both fluorescence in situ hybridization and next-generation sequencing to provide clinicians with information.
The new laboratory, which began trial operations this week, is designed to test 10,000 samples per day for the 2019-nCoV coronavirus.
Paired tumor/germline analysis is not routinely done in cancer care, but some labs are starting to report incidental germline findings alongside patient's tumor profiles.